Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Non-Current Deffered Revenue (2024 - 2025)

BioAge Labs' Non-Current Deffered Revenue history spans 2 years, with the latest figure at $556000.0 for Q3 2025.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $556000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $556000.0, a N/A change, with the full-year FY2024 number at $4.7 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue hit $556000.0 in Q3 2025 for BioAge Labs, down from $1.9 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for BIOA hit a ceiling of $4.7 million in Q4 2024 and a floor of $556000.0 in Q3 2025.